Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2016', provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) - The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects - The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hospital Acquired Pneumonia (HAP) Overview 9 Therapeutics Development 10 Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview 10 Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 11 Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies 12 Hospital Acquired Pneumonia (HAP) - Therapeutics under Investigation by Universities/Institutes 14 Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Hospital Acquired Pneumonia (HAP) - Products under Development by Companies 19 Hospital Acquired Pneumonia (HAP) - Products under Investigation by Universities/Institutes 21 Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 22 Achaogen Inc. 22 Adenium Biotech ApS 23 Aridis Pharmaceuticals LLC 24 AstraZeneca Plc 25 Cardeas Pharma Corp. 26 MedImmune, LLC 27 Meiji Seika Pharma Co., Ltd. 28 Melinta Therapeutics, Inc 29 Merck & Co., Inc. 30 Motif Bio Plc 31 Nabriva Therapeutics AG 32 Savara Inc. 33 Tetraphase Pharmaceuticals Inc. 34 Wockhardt Limited 35 Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 (amikacin + fosfomycin) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 (avibactam + ceftazidime) - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 (ceftolozane sulfate + tazobactam sodium) - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 (cilastatin sodium + imipenem + relebactam) - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AA-139 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Aerucin - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 arbekacin - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 delafloxacin - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 eravacycline - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 fosfomycin tromethamine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 iclaprim mesylate - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 lefamulin acetate - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 MEDI-3902 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MEDI-4893 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Nu-2 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Panaecin - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 panobacumab - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 plazomicin sulfate - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Qn-2251 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 tedizolid phosphate - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 tosatoxumab - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 vancomycin hydrochloride - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 WCK-2349 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 WCK-5222 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 WCK-771 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Hospital Acquired Pneumonia (HAP) - Recent Pipeline Updates 91 Hospital Acquired Pneumonia (HAP) - Dormant Projects 121 Hospital Acquired Pneumonia (HAP) - Discontinued Products 122 Hospital Acquired Pneumonia (HAP) - Product Development Milestones 123 Featured News & Press Releases 123 Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 123 Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 123 Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured 123 Oct 13, 2015: Motif Bio Announces Results of Two Posters on Iclaprim at ID Week 2015 124 Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015 125 Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 125 Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 126 Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA 126 Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline's Potential Activity in Treating Serious Respiratory Infections 127 Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 128 Appendix 130 Methodology 130 Coverage 130 Secondary Research 130 Primary Research 130 Expert Panel Validation 130 Contact Us 130 Disclaimer 131
List of Tables Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2016 10 Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H1 2016 22 Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2016 23 Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 24 Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2016 25 Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp., H1 2016 26 Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H1 2016 27 Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 28 Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H1 2016 29 Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co., Inc., H1 2016 30 Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2016 31 Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H1 2016 32 Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc., H1 2016 33 Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 34 Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Limited, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Assessment by Combination Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Hospital Acquired Pneumonia (HAP) Therapeutics - Recent Pipeline Updates, H1 2016 91 Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2016 121 Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2016 122
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
